US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.10 against a street estimate of -0.07 — a miss of 42.9%.
Analysts rate Hims Hers Health Inc a hold (3 buy, 11 hold, 1 sell out of 15) with an average price target of $31.15.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.30% |
| Vanguard Portfolio Management, LLC | 4.53% |
| Vanguard Capital Management, LLC | 4.09% |
| State Street Corp | 3.49% |
| Morgan Stanley - Brokerage Accounts | 3.07% |
| Divisadero Street Capital Management, LP | 2.58% |
| Geode Capital Management, LLC | 2.44% |
| The Goldman Sachs Group Inc | 2.22% |
| Document | Date |
|---|---|
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Hims & Hers appointed Jonathan M. Franklin as principal accounting officer, effective October 9, 2026. • Franklin joined the comp | 2026-10-07 |
| Quarterly report · Q2 2026 HIMS & HERS HEALTH, INC. - 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 Revenue: $753.2 million (up 38% from $544.8 million in Q2 20 | 2026-08-10 |
| Results announced · Q3 2026 HIMS & HERS HEALTH, INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $753.2 million, up 38% year-over-year • Q2 2026 subscribers: | 2026-08-10 |
| Board / officer change · Q3 2026 HIMS & HERS HEALTH, INC. – DOCUMENT SUMMARY OTHER NOTABLE POINTS • Chief Accounting Officer Resignation: Irene Becklund resigned as Chief Accounting | 2026-07-17 |
| Material agreement · Q2 2026 HIMS & HERS HEALTH, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Receivables Purchase Agreement facility limit: $400,000,000 with JPMorgan Chase Bank, | 2026-07-01 |
| Shareholder vote results · Q2 2026 HIMS & HERS HEALTH, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 11, 2026 • 222,525,754 shares of Class A Common | 2026-06-15 |
| Quarterly report · Q1 2026 HIMS & HERS HEALTH, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $608.1 million (up from $586.0 million in Q1 2025; +3.8% YoY) • | 2026-05-11 |
| Proxy statement · Q2 2026 HIMS & HERS HEALTH, INC. – PROXY SUMMARY FOR RETAIL INVESTORS --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 9 director nominees to serve | 2026-04-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Eucalyptus with credit facility amendment Hims & Hers Health, Inc. completed its acquisition of Eucalyptus (an Australian telehealth company) on June 2, 2026. To facilitate this deal, the company amended its revolving credit facilit | 2026-06-02 |
| Acquires Australian digital health company Eucalyptus for up to $1.15B Hims & Her Health agreed to acquire Eucalyptus, an Australian-based digital health company operating in Australia, UK, Germany, Canada, and Japan, for approximately $1.15 billion. The deal s | 2026-02-19 |
| Board authorizes new $250M share repurchase program through 2028 Hims & Hers Health's board approved a new $250 million share repurchase program on November 13, 2025, valid through November 2028. The company will buy back its own Class A common stock at m | 2025-11-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Hims Hers Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.